MedTrace Logo

Alpha-lipoic Acid in Diabetic Nephropathy

NCT06253429 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-02-12

No results posted yet for this study

Summary

Endothelial dysfunction in diabetes is a central event in the pathogenesis of different microangioapthic changes. Nephropathy in patients with type 1 diabetes is a severe microvascular complication.

Conditions

Interventions

DRUG

Thioctic Acid 333 MG Oral Capsule

Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes

DRUG

Captopril 25Mg Tab

Oral angiotensin-converting enzyme inhibitors

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Yasmine I Elhenawy · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-01-31
Completion
2024-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06253429 on ClinicalTrials.gov